Bibliografía:

1: de Paiva NM, Ayrizono ML, Milanski M, Coope A, Oliveira LM, Fagundes JJ, Velloso LA, Coy CS, Leal RF. Differential expression of TLR2, TLR4 and JNK in mucosa of ileal pouches for ulcerative colitis. Is there a role for bacterial antigen pathway in asymptomatic patients? Int J Clin Exp Med. 2011;4(3):179-86.
2: Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis. Gastroenterology. 2011 Oct;141(4):1194-201.
3: Yokoyama Y, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, Iimuro M, Yoshida K, Kikuyama R, Kato K, Nagase K, Nakamura S, Miwa H, Matsumoto T. The CD4(+)CD28(null) and the regulatory CD4(+)CD25(High) T-cell phenotypes in patients with ulcerative colitis during active and quiescent disease, and following colectomy. Cytokine. 2011 Nov;56(2):466-70.
4: Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, Howarth D, Campbell F, Rhodes JM. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut. 2011 Nov;60(11):1520-6.